These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 16018851

  • 1. Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension.
    Tonstad S, Tykarski A, Weissgarten J, Ivleva A, Levy B, Kumar A, Fitchet M.
    Am J Cardiol; 2005 Jul 15; 96(2):243-51. PubMed ID: 16018851
    [Abstract] [Full Text] [Related]

  • 2. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects.
    Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M, OBES-002 Study Group.
    Int J Obes Relat Metab Disord; 2004 Nov 15; 28(11):1399-410. PubMed ID: 15486569
    [Abstract] [Full Text] [Related]

  • 3. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects.
    Astrup A, Caterson I, Zelissen P, Guy-Grand B, Carruba M, Levy B, Sun X, Fitchet M.
    Obes Res; 2004 Oct 15; 12(10):1658-69. PubMed ID: 15536230
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    Toplak H, Hamann A, Moore R, Masson E, Gorska M, Vercruysse F, Sun X, Fitchet M.
    Int J Obes (Lond); 2007 Jan 15; 31(1):138-46. PubMed ID: 16703004
    [Abstract] [Full Text] [Related]

  • 5. A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients.
    Rosenstock J, Hollander P, Gadde KM, Sun X, Strauss R, Leung A, OBD-202 Study Group.
    Diabetes Care; 2007 Jun 15; 30(6):1480-6. PubMed ID: 17363756
    [Abstract] [Full Text] [Related]

  • 6. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity.
    Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M, Perry BH.
    Obes Res; 2003 Jun 15; 11(6):722-33. PubMed ID: 12805393
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.
    Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, Brandes JL, Bigal M, Saper J, Ascher S, Jordan DM, Greenberg SJ, Hulihan J, Topiramate Chronic Migraine Study Group.
    Headache; 2007 Feb 15; 47(2):170-80. PubMed ID: 17300356
    [Abstract] [Full Text] [Related]

  • 8. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs.
    Dodick DW, Freitag F, Banks J, Saper J, Xiang J, Rupnow M, Biondi D, Greenberg SJ, Hulihan J, CAPSS-277 Investigator Group.
    Clin Ther; 2009 Mar 15; 31(3):542-59. PubMed ID: 19393844
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ, Leibowitz MT, Weinstein SP, Rowe ED, Mendel CM, Levy B, McMahon FG, Mullican WS, Toth PD, Cutler NR.
    J Hum Hypertens; 2002 Jan 15; 16(1):13-9. PubMed ID: 11840225
    [Abstract] [Full Text] [Related]

  • 10. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K, Sibutramine in Hypertensives Clinical Study Group.
    J Hum Hypertens; 2002 Jan 15; 16(1):5-11. PubMed ID: 11840224
    [Abstract] [Full Text] [Related]

  • 11. Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial.
    Eliasson B, Gudbjörnsdottir S, Cederholm J, Liang Y, Vercruysse F, Smith U.
    Int J Obes (Lond); 2007 Jul 15; 31(7):1140-7. PubMed ID: 17264849
    [Abstract] [Full Text] [Related]

  • 12. Topiramate: a new potential pharmacological treatment for obesity.
    Astrup A, Toubro S.
    Obes Res; 2004 Dec 15; 12 Suppl():167S-73S. PubMed ID: 15687413
    [Abstract] [Full Text] [Related]

  • 13. Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m(2).
    Davidson MH, Tonstad S, Oparil S, Schwiers M, Day WW, Bowden CH.
    Am J Cardiol; 2013 Apr 15; 111(8):1131-8. PubMed ID: 23375187
    [Abstract] [Full Text] [Related]

  • 14. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study.
    McElroy SL, Hudson JI, Capece JA, Beyers K, Fisher AC, Rosenthal NR, Topiramate Binge Eating Disorder Research Group.
    Biol Psychiatry; 2007 May 01; 61(9):1039-48. PubMed ID: 17258690
    [Abstract] [Full Text] [Related]

  • 15. Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes.
    Stenlöf K, Rössner S, Vercruysse F, Kumar A, Fitchet M, Sjöström L, OBDM-003 Study Group.
    Diabetes Obes Metab; 2007 May 01; 9(3):360-8. PubMed ID: 17391164
    [Abstract] [Full Text] [Related]

  • 16. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
    Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, Day WW.
    Lancet; 2011 Apr 16; 377(9774):1341-52. PubMed ID: 21481449
    [Abstract] [Full Text] [Related]

  • 17. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH).
    Palma Gámiz JL, Pêgo M, Contreras EM, Anglada MP, Martínez JO, Esquerra EA, Sagastagoitia Gorostiza JD, Iberian Multicenter Imidapril Study on Hypertension.
    Clin Ther; 2006 Dec 16; 28(12):2040-51. PubMed ID: 17296460
    [Abstract] [Full Text] [Related]

  • 18. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
    García-Morales LM, Berber A, Macias-Lara CC, Lucio-Ortiz C, Del-Rio-Navarro BE, Dorantes-Alvárez LM.
    Clin Ther; 2006 May 16; 28(5):770-82. PubMed ID: 16861099
    [Abstract] [Full Text] [Related]

  • 19. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
    Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, Schwiers M, Day WW, Bowden CH.
    Am J Clin Nutr; 2012 Feb 16; 95(2):297-308. PubMed ID: 22158731
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension.
    Germino FW.
    Clin Ther; 2009 Sep 16; 31(9):1946-56. PubMed ID: 19843484
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.